---
title: "Proposed Merger Poses Operational and Valuation Risks for Select Medical"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284958233.md"
description: "Select Medical (SEM) has identified new risks related to its proposed merger, which may disrupt operations regardless of the transaction's outcome. Potential issues include employee attrition, management distraction, strained stakeholder relationships, and reduced strategic flexibility, all of which could impact results and valuation. Currently, Wall Street holds a consensus rating of Hold on SEM stock, based on three Hold ratings."
datetime: "2026-05-02T06:00:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284958233.md)
  - [en](https://longbridge.com/en/news/284958233.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284958233.md)
---

# Proposed Merger Poses Operational and Valuation Risks for Select Medical

Select Medical (SEM) has disclosed a new risk, in the Corporate Activity and Growth category.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The announcement and pendency of the proposed Merger is likely to disrupt Select Medical’s operations, regardless of whether the transaction ultimately closes. Investor should consider risks such as employee attrition, diverted management attention and cash resources, strained stakeholder relationships, and limitations on strategic flexibility, all of which could pressure its results and valuation.

Overall, Wall Street has a Hold consensus rating on SEM stock based on 3 Holds.

To learn more about Select Medical’s risk factors, click here.

### Related Stocks

- [SEM.US](https://longbridge.com/en/quote/SEM.US.md)

## Related News & Research

- [A Look At Select Medical Holdings (SEM) Valuation As Recent Performance And Models Send Mixed Signals](https://longbridge.com/en/news/286863175.md)
- [A Look At Select Medical Holdings (SEM) Valuation As Shares Track Narrative Fair Value](https://longbridge.com/en/news/285869425.md)
- [Leverage, Covenants and Royalty Drain: Why Tuhura Biosciences’ Parkview Credit Deal Heightens Liquidity and Dilution Risks](https://longbridge.com/en/news/286663837.md)
- [BlackRock private credit fund valuation practices under investigation - report](https://longbridge.com/en/news/286621253.md)
- [Calidi Biotherapeutics GAAP EPS of -$0.43](https://longbridge.com/en/news/286474175.md)